Evidence map›Paper›PMID 42662861›Full record

ArticleJournal of pathology informatics2026

Lessons learned from the validation of a machine learning-based colorectal carcinoma screening pipeline in sub-Saharan Africa.

Alfred Githuka, Ulysses G J Balis, Ye Chan Kim, Eileen M Weinheimer-Haus, Christopher L Williams, Jerome Y Cheng, Kelou Yao, John Blau, Jessica A Baker, Priscilla Njenga and 5 more

Abstract read
In one paragraph

Article in Journal of pathology informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alfred GithukaDepartment of Hematology-Oncology, Aga Khan University Hospital Nairobi, Nairobi, Kenya.
Ulysses G J BalisDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Ye Chan KimDepartment of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA.
Eileen M Weinheimer-HausDepartment of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA.
Christopher L WilliamsDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Jerome Y ChengDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Kelou YaoDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
John BlauDepartment of Pathology, University of Iowa, Iowa, IA, USA.
Jessica A BakerCenter for Global Health and Equity, University of Michigan, Ann Arbor, MI, USA.
Priscilla NjengaDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Winny ChepkemoiDepartment of Surgery, AGC Tenwek Hospital, Bomet, Kenya.
Robert K ParkerDepartment of Surgery, AGC Tenwek Hospital, Bomet, Kenya.
Akbar K WaljeeDepartment of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA.
Shahin SayedDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Mansoor N SalehDepartment of Hematology-Oncology, Aga Khan University Hospital Nairobi, Nairobi, Kenya.

Funding

Leveraging artificial intelligence/machine learning-based technology to overcome specialized training and technology barriers for the diagnosis and prognostication of colorectal cancer in AfricaU01CA287852 · NCI · AGA KHAN UNIVERSITY (KENYA) · PI BALIS, ULYSSES GREGORY JOHN, RAO, ARVIND · 2023 to 2025
$750k
NCI NIH HHS U01 CA287852
6 · The paper itself

Abstract

Background: Artificial intelligence for digital pathology may improve cancer detection and workflow efficiency in low- and middle-income countries, but most models are trained and validated in high-income settings, creating uncertainty about generalizability and real-world deployability under differing pre-analytic and infrastructure conditions. Objective: To validate a locally optimized colorectal carcinoma screening pipeline, retrained on data from a local Kenyan cohort, and to assess its feasibility as a sensitivity-forward assistive pre-screening workflow. Methods: Formalin-fixed, paraffin-embedded hematoxylin and eosin-stained slides from 136 biopsy-proven colonic adenocarcinoma cases and 20 normal controls from 2 Kenyan institutions were digitized at 40× using a Grundium Ocus scanner. Whole-slide images were partitioned at the case level. A feature-enrichment and candidate tile-selection step identified adenocarcinoma-rich regions. Candidate 512 × 512 RGB tiles were then adjudicated by a gastrointestinal pathologist into adenocarcinoma-containing and benign/non-neoplastic tile libraries. These expert-curated tiles were used to train and validate a supervised convolutional neural network classifier, which generated tile-level malignancy probabilities. Tile scores were aggregated into case-level predictions using Top-K pooling and positive-tile burden rules to support sensitivity-forward screening. Results: Among 14,452 tiles from 70 quality-controlled cases and 19 controls, the model achieved strong tile-level discrimination (sensitivity 0.9548, specificity 0.9926, F1 score 0.9686, and AUROC curve 0.966); case-level Top-K aggregation achieved an AUROC of 1.0. Conclusion: A locally optimized computational pathology screening pipeline, based on data from a local population, demonstrated robust colorectal adenocarcinoma detection in a Kenyan cohort. These findings suggest that existing machine-learning models can be adapted to local populations through retraining with locally derived data.

Indexed as

Artificial intelligenceColorectal adenocarcinomaComputational pathologyDigital pathologyKenyaLow- and middle-income countriesScreening

Identifiers

PMID42662861
PMCPMC13521063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.